MPL utilizes a proprietary technology platform to deliver small molecule drugs to tumor-associated macrophages in a highly selective manner, activating the body's immune system against cancer. The company's approach has been clinically validated and offers the potential for both best-in-class drugs against known targets and first-in-class molecules for novel targets. MPL is led by a highly experienced executive team and supported by a Board of Directors and Scientific Advisory Board comprised of leading figures in the biopharma and investment communities. With a strong emphasis on high impact science and commercial awareness, MPL aims to deliver innovative therapies that leverage the body's own defenses to combat cancer.